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Growth hormone treatment and risk of malig­
nancy
Hyun-Wook Chae, MD1, Duk-Hee Kim, MD, PhD2, Ho-Seong Kim, MD, PhD1
1Department of Pediatrics, Endocrine Research Institute, Yonsei University College of Medicine, Soul, 2Sowha Children’s Hospital, Seoul, Korea 
Growth hormone (GH) treatment has been increasingly widely used for children with GH deficiencies 
as the survival rate of pediatric patients with malignancies has increased. Both GH and insulin-like 
growth factor-I have mitogenic and antiapoptotic activity, prompting concern that GH treatment may 
be associated with tumor development. In this review, the authors examined the relationship between 
GH treatment and cancer risk in terms of de novo malignancy, recurrence, and secondary neoplasm. 
Although the results from numerous studies were not entirely consistent, this review of various clinical 
and epidemiological studies demonstrated that there is no clear evidence of a causal relationship 
between GH treatment and tumor development. Nonetheless, a small number of studies reported that 
childhood cancer survivors who receive GH treatment have a small increased risk of developing de novo 
cancer and secondary malignant neoplasm. Therefore, regular follow-ups and careful examination 
for development of cancer should be required in children who receive GH treatment. Continued 
surveillance for an extended period is essential for monitoring long-term safety.
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Introduction 
Growth hormone (GH) has been administered to children with GH deficiency since the 
late 1950s, initially using extracts from human pituitary glands1). Since the 1980s, GH 
has been produced by recombinant DNA technology and prescribed for a wide variety 
of disorders. As the use of synthetic human recombinant GH has increased over the past 
several decades, there has been a concurrent increase in awareness of the potential safety 
issues accompanying the treatment2). Recently, Carel et al.3) analyzed a French population-
based registry of 6,928 children who started GH treatment between 1985 and 1996. The 
researchers reported that mortality rates increased in children treated with recombinant GH; 
however, all types of cancer-related mortality did not increase, and most of the increased 
mortality was due to bone tumors or cerebral hemorrhage. This exemplifies the controversy 
associated with GH treatment and risk of malignancy.
Survival rates of pediatric patients with malignancies are increasing due to improved 
treatment modalities, and interest in improved, long-term quality of life is increasing in 
tandem, including optimizing the final height of a patient with GH deficiency after cancer 
treatment4). For patients with GH deficiency after completing antitumor therapy, GH is 
often recommended to increase height velocity and improve quality of life5). 
On its own, however, GH has mitogenic activity6). There have been theoretical and 
clinical concerns that GH may play a part in tumor recurrence7,8). GH treatment may 
increase an individual’s risk of developing cancer, particularly in the case of cancer 
survivors, by increasing the risk of recurrence or secondary malignancy9). Controversies 
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and debates are currently ongoing regarding GH treatment’s 
possible causal relationship with tumor recurrence.
It is known from in vitro and in vivo studies that GH and 
insulin-like growth factor-I (IGF-I) have mitogenic and anti-
apoptotic activity, and it is possible that GH treatment may 
be associated with tumor development7,8). Higher serum levels 
of IGF-I may also be associated with increased cancer risk, 
and concern has been raised regarding its potential role as a 
carcinogen after GH treatment10). Some epidemiological studies 
have shown a correlation between high serum levels of IGF-I 
and occurrence of certain cancers, including carcinomas of 
the prostate, lung, breast, and colon11,12). GH receptors have 
been expressed on normal and transformed human white 
blood cells, and in vitro studies have shown that GH may cause 
transformation of normal cells and proliferation of leukemic 
cells9,13). Most of IGF-I’s physical effects are mediated through the 
type 1 IGF receptor, which is overexpressed in many different 
types of cancers14). Although the results of all studies are not 
completely consistent, a high concentration of IGF-I may be 
linked to an increased risk of cancer development15).
As with IGF-I, there is a concern that GH treatment may be 
associated with tumor development. Although GH treatment has 
been shown to be generally safe, it is important to investigate the 
relationship between GH treatment and cancer risk. The authors 
reviewed clinical and epidemiological studies that examined 
cancer risk in patients treated with GH with a focus on de novo 
malignancy, recurrence, and secondary neoplasm.
GH treatment and de novo malignancy
1. Leukemia
A possible correlation between GH therapy and increased risk 
of leukemia was reported in Japan16); however, the investigators 
carried out a follow-up analysis of the cohort and could not find 
a close association between GH therapy and leukemia when 
subjects with known risk factors for leukemia were excluded17). 
The United States’ National Hormone Pituitary Program found 
3 cases of leukemia in 59,736 patient-years of GH treatment 
between 1963 and 1985. The rate was not significantly higher 
than the 1.6 cases expected for an age, ethnicity, and sex-
matched population18). Genentech’s National Cooperative Growth 
Study (NCGS), which enrolled more than 40,000 GH recipients 
during 20 years of follow-up, showed that the leukemia risk was 
comparable to that of the general population when subjects with 
known risk factors for leukemia were excluded19). Another study 
from the NCGS reported 3 cases of de novo leukemia compared 
with the 5.6 cases expected in a theoretical, age-matched general 
population20).
2. Solid tumors
There has been concern that elevated endogenous levels of 
GH and IGF-I might be associated with an increased risk of 
certain solid tumors. Swerdlow et al.21) studied cancer incidence 
and mortality in 1,848 patients in the UK who were treated with 
human pituitary GH during childhood and early adulthood 
between 1959 and 1985. The incidence and mortality of 
colorectal cancer and the mortality of Hodgkin's disease initially 
increased after patients with an otherwise high risk of cancer were 
excluded. Since then, however, the validity of the results have 
been debated, because the current GH therapy regimen differs 
from what was used at the time8). All patients received standard 
GH doses given 2 or 3 times a week, and serum IGF-I levels were 
not monitored. 
Tyden et al.22) reported 2 cases of de novo development of 
cancer in living kidney transplant recipients, although de novo 
development of cancer in renal transplants might be rare. 
According to the analysis from the Kabi International Growth 
Study (KIGS) and NCGS databases, however, only 2 cases of 
renal cell carcinoma in those who did not have renal disease 
were found among the 43,000 patients in the NCGS registry 
and 42,000 in the KIGS registry23). The number of malignancies 
seemed disproportionately high for the relatively small number 
of children who had chronic renal failure and who were receiving 
GH treatment8,23).
Tuffli et al.24) reported that the number of extracranial, non-
leukemic neoplasms from 12,209 individuals who were treated 
with the recombinant GH was no greater than expected cases. 
Although 10 new cases of malignancies were noted, it was 
not a greater value than predicted, indicating that GH was not 
implicated in the occurrence of solid tumors. Another report 
from NCGS showed no evidence of an increase in the incidence 
of de novo intracranial tumors in children treated with GH25). 
Bell et al.20) reported, from a recent analysis of the NCGS registry, 
that de novo intracranial and extracranial malignancies were 
not significantly increased in patients without risk factors (29 
confirmed vs. 26 expected). One of the most recent reports from 
the KIGS compared the incidence of cancer in the cohort to that 
in the general population by using the standardized incidence 
ratio (SIR)26). A total of 32 new malignant neoplasms were 
reported in 58,603 patients, versus the 25.3 expected (SIR, 1.26; 
95% confidence interval [CI], 0.86–1.78). Again, patients treated 
with GH showed no statistically significant difference in cancer 
incidence compared with the expected number of cases in this 
study. 
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GH treatment and recurrence of malignancy
1. Leukemia
Survivors of childhood leukemia are at risk of developing 
complications, including growth failure, which may require 
GH treatment8). Patients with GH deficiency are particularly 
common because total body irradiation increases risk of growth 
failure, although GH deficiency can also result from solely 
chemotherapeutic regimens27). There has been concern that 
children treated with GH after therapy against leukemia may be 
at a higher risk of leukemia recurrence.
Leung et al.28) studied 47 patients who had received GH replace-
ment therapy among 910 patients treated for acute lymphoblastic 
leukemia and examined recurrence rates at 7 years and 11 years 
after continuous hematologic remission. There was no statistical 
evidence that GH therapy was associated with leukemia relapse or 
development of a second malignancy.
The NCGS has monitored the safety of recombinant human 
GH since 1985. There have been 3 new cases of leukemia in 
children without known risk factors for developing leukemia 
and 5 cases in children with known risk factors; however, there 
was no evidence of an increased recurrence of leukemia29). 
Follow-up reports showed no evidence of increased incidence of 
leukemia among patients without previous risk factors30). Another 
investigator analyzed 47,000 patients representing 165,000 
patient-years from the NCGS and found reassuring evidence 
that leukemia (de novo or relapse), extracranial nonleukemic 
neoplasms, and central nervous system (CNS) tumor recurrence 
were not associated with GH therapy31).
Sklar et al.32) investigated 122 acute leukemia survivors from 
among 13,539 subjects enrolled in the Childhood Cancer Survivor 
Study (CCSS), a cohort of 5-year survivors of childhood cancer. 
They found that the relative risk of recurrence was not increased 
compared to 4,545 children not treated with GH.
2. Brain tumors
GH deficiency is a common disease in patients with hypothala-
mic-pituitary tumors. The deficiency is caused either by the mass 
itself or by surgical or irradiation therapy to hypothalamopituitary 
axis9). Deficiency can also develop in those who have tumors 
far from the hypothalamopituitary axis, because cerebrospinal 
irradiation is often needed to treat these tumors33).
In 1985, Arslanian et al.34) reported the outcome of GH therapy 
in 34 children with brain tumors who developed hypopituitarism. 
Of the 34 patients with brain tumors and hypopituitarism, 24 
received GH therapy. Eight of the 24 (33%) experienced tumor 
recurrence, compared with 3 of the 10 (30%) who did not receive 
GH. Clayton et al.35) reported similar results, namely that the late 
relapse rate of medulloblastoma and glioma was not altered by 
GH therapy, and the therapy might not increase the relapse rate 
of brain tumors.
Medulloblastoma is one of the most malignant childhood 
brain tumors. Survivors of medulloblastoma are, however, 
increasing as progress has been made in the treatment of the 
tumor36). From a retrospective analysis of 34 children treated 
with GH for medulloblastoma over 3 years, Chae et al.37) reported 
no cases of recurrence. Another retrospective review included 
545 children with medulloblastoma, of whom 170 patients were 
treated with GH38). This review found that while GH treatment 
was underutilized in survivors of medulloblastoma, it was not 
associated with disease relapse.
Craniopharyngioma is a relatively common brain tumor de-
rived from pituitary gland embryonic tissue in children39). Due 
to the morbidities associated with damage to the pituitary and 
hypothalamus from surgical removal and irradiation against 
craniopharyngioma, GH treatment is commonly needed after 
therapy to treat this tumor40). The recurrence rate of cranio-
pharyngioma was 0.045/treatment year in 488 patients who were 
enrolled in the KIGS from 1988 to 1996, and the investigators 
concluded that GH treatment might be safe and effective in children 
with craniopharyngioma41). In the NCGS report, children receiving 
GH after treatment for craniopharyngioma had a recurrence rate 
of 6.4%, considerably lower than the estimates of 20%–25% in 
another report25,42).
Swerdlow et al.43) investigated 180 children with brain tumors 
treated with GH, and 891 children not treated with GH during 
1965–1996. The relative risk of first recurrence in GH-treated 
patients decreased after adjusting for potentially confounding 
prognostic variables (0.6; 95% CI, 0.4–0.9). The relative risk of 
mortality also decreased (0.5; 95% CI, 0.3–0.8). There was no 
significant trend in relative risk of recurrence with cumulative 
time for which GH treatment had been given or with time 
elapsed since GH treatment started. Another study showed, 
using surveillance imaging, that hypothalamopituitary tumor 
recurrence in GH-treated patients was as low as in non–GH-
treated patients44). Only 1 patient among 100 consecutive patients 
showed evidence of slight intrasellar tissue enlargement using 
pituitary imaging at 6 months. GH replacement was continued, 
and there was no further change between 6 and 12 months, 
though the follow-up duration was short and may not be con-
clusive evidence against recurrence. 
GH treatment and risk of secondary malignancy
Childhood cancer survivors might be at increased risk for 
secondary malignancies compared with the general population45). 
Assessing their risk of second and subsequent malignancies 
during long term follow-up is thus very important. 
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Meadows et al.46) investigated 14,358 cohort members in the 
CCSS and analyzed SIRs for occurrences of a second malignant 
neoplasm. The 30-year cumulative incidence of second malignant 
neoplasm was 9.3%, and the risk of subsequent neoplasms 
remained elevated for more than 20 years of follow-up for all 
diagnoses of primary childhood cancer. Another report from 
the CCSS showed that the risk of sarcoma was more than 9 
folds greater among childhood cancer survivors than among 
the general population47). Ergun-Longmire et al.48) analyzed the 
cohort and reported that the rate of GH-treated survivors de-
veloping secondary neoplasms was 2.1 folds greater compared 
with non–GH-treated survivors; however, the risk appeared to 
decrease as follow-up time extended. Using large cohort follow-
up studies, Carel and Butler49) suggested that children treated 
with GH following childhood cancer treatment might not have 
a greater number of relapses, but that there might be a higher 
incidence of secondary tumors in the early years of GH therapy. 
There are, however, some more reassuring data. Neglia et al.50) 
analyzed 13,581 children from a retrospective cohort drawn from 
US and Canadian institutions who were diagnosed with common 
cancers before the age of 21 and survived at least 5 years. 
Twenty years after the childhood cancer diagnosis, the estimated 
cumulative incidence of second malignancy was 3.2%, and only 
1.88 excess malignancies occurred during follow-up. Sklar et al.32) 
studied 172 brain tumor survivors from among 13,539 survivors 
enrolled in the CCSS. The relative risk of disease recurrence was 
0.83 (95% CI, 0.37–1.86) for survivors who had been treated 
with GH, and risk was not increased for any of the major cancer 
diagnoses. 
Most recently, Patterson et al.51) analyzed 12,098 pediatric 
cancer survivors from the CCSS and reported the incidence of 
meningioma, glioma, and other solid CNS tumors. The adjusted 
rate of CNS tumor development in patients treated with GH 
compared with untreated survivors was 1.0 (95% CI, 0.6–1.8). 
Overall, there was no statistically significant increase in risk 
of the occurrence of solid CNS tumors associated with GH 
exposure. Major recent studies of growth hormone treatment and 
malignancy risk from large data registries were summarized in 
Table 1.
Levels of circulating IGF-I might be associated with an in-
creased risk of common cancers, although the association re-
mains unclear52), as there have been few large cohort studies 
studying the relationship between GH dosage, IGF-I levels, and 
risk of tumor recurrence. A meta-analysis and systematic re-
view showed that high concentrations of IGF-I were associated 
with an increased risk of prostate cancer and premenopausal 
breast cancer, but the associations were modest52). Nonetheless, 
monitoring and maintaining IGF-I levels within a normal range 
might be important, and titrating GH doses to target IGF-I levels 
(IGF-I based dosing) could be a reasonable approach in this high 
risk GH-treated group49).
Conclusions
The benefits of GH treatment for growth and metabolism in 
children with GH deficiency are well defined, and replacement 
therapy with GH is recommended53). Despite theoretical concerns 
about the effect of GH on tumor development, this review of 
various clinical and epidemiological studies demonstrated that 
there is no clear evidence of a causal relationship between GH 
treatment in patients with GH deficiency and tumor development. 
Nonetheless, a small number of studies have reported that 
childhood cancer survivors who have received GH treatment have 
a small increased risk of de novo cancer and second malignant 
neoplasm. Therefore, regular follow-ups and careful examination 
for the development of cancer should be required in those who 
receive GH treatment. Continued surveillance for an extended 
period is essential to monitor further potential changes.
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Table 1. Major recent studies of growth hormone treatment and malignancy risk (large data registries)
Source Year of publication Data registry
No. of 
patients
No. of 
observed cases
No. of 
expected cases SIR (95% CI) Type of observed malignancy
Patterson et al.51) 2014 CCSS 14,358 16 -   1.0 (0.6–1.8) Secondary CNS malignancy
Wilton et al.26) 2010 KIGS 58,603 32 25.3 1.26 (0.86–1.78) De novo malignancy
Bell et al.20) 2010 NCGS 54,996 29 26.0 1.12 (0.75–1.61) De novo nonleukemic malignancy
  3   5.6 0.54 (0.11–1.58) De novo leukemia
Wyatt31) 2004 NCGS 47,000 16 15.3 - Recurred nonleukemic malignancy
Maneatis et al.30) 2000 NCGS 33,161 20 - 0.73 (0.20–1.86) Reccurred leukemia 
35 - 0.44 (0.24–0.74) Recurred nonleukemic malignancy
SIR, standardized incidence ratio; CI, confidence interval; CCSS, the Childhood Cancer Survivor Study; CNS, central nervous system; KIGS, the Kabi International 
Growth Study; NCGS, the National Cooperative Growth Study.
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